CIMADAMORE, Alessia
 Distribuzione geografica
Continente #
NA - Nord America 7.841
EU - Europa 1.376
AS - Asia 745
AF - Africa 180
SA - Sud America 7
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.152
Nazione #
US - Stati Uniti d'America 7.833
IE - Irlanda 428
SG - Singapore 357
CN - Cina 281
SE - Svezia 242
IT - Italia 235
CI - Costa d'Avorio 165
DE - Germania 124
UA - Ucraina 114
GB - Regno Unito 105
IN - India 66
FR - Francia 33
FI - Finlandia 22
KR - Corea 17
BE - Belgio 15
RU - Federazione Russa 14
MA - Marocco 12
DK - Danimarca 11
RO - Romania 7
JP - Giappone 6
BR - Brasile 5
CA - Canada 5
NL - Olanda 5
IL - Israele 4
BG - Bulgaria 3
LU - Lussemburgo 3
MX - Messico 3
AU - Australia 2
CO - Colombia 2
CZ - Repubblica Ceca 2
ES - Italia 2
KZ - Kazakistan 2
LY - Libia 2
PK - Pakistan 2
PL - Polonia 2
SK - Slovacchia (Repubblica Slovacca) 2
TR - Turchia 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AT - Austria 1
CH - Svizzera 1
EU - Europa 1
HR - Croazia 1
HU - Ungheria 1
ID - Indonesia 1
IR - Iran 1
IS - Islanda 1
LI - Liechtenstein 1
MY - Malesia 1
NP - Nepal 1
RS - Serbia 1
SA - Arabia Saudita 1
TN - Tunisia 1
VN - Vietnam 1
Totale 10.152
Città #
Des Moines 1.470
Chandler 1.178
Fairfield 666
Ashburn 579
Dublin 420
Wilmington 345
Boardman 314
Woodbridge 282
Houston 249
Seattle 245
Cambridge 214
Jacksonville 199
Lawrence 167
Princeton 167
Abidjan 165
San Mateo 142
Ann Arbor 135
Singapore 125
New York 116
San Diego 100
Washington 73
Redmond 72
Pune 65
Los Angeles 49
London 41
Dallas 32
Falls Church 31
Beijing 30
Ancona 28
Shanghai 27
Wuhan 26
Guangzhou 23
Helsinki 21
Norwalk 19
Turin 17
Brussels 15
Jiaxing 14
Prescot 10
Forlì 9
Rome 9
Seoul 9
Centro 8
Edinburgh 7
Strasbourg 7
Wuxi 7
Cagliari 6
Fuzhou 6
Menlo Park 6
Southwark 6
Tolentino 6
Yiwu 6
Chicago 5
Hounslow 5
Marche 5
Nanjing 5
Phoenix 5
Shenzhen 5
Stockholm 5
Bologna 4
Canosa di Puglia 4
Clifton 4
Kilburn 4
Marano di Valpolicella 4
Redwood City 4
Amsterdam 3
Buffalo 3
Fayetteville 3
Frankfurt am Main 3
Gatchina 3
Heze 3
Jinhua 3
Milan 3
New Bedfont 3
Pesaro 3
Portland 3
Saint Petersburg 3
Santa Clara 3
Sofia 3
Tokyo 3
Toronto 3
Torre Del Greco 3
Wandsworth 3
Antalya 2
Appignano 2
Augusta 2
Brasília 2
Campobasso 2
Chiswick 2
Città di Castello 2
Civitanova Marche 2
Falconara Marittima 2
Heidelberg 2
Islamabad 2
Jinan 2
Kagoya 2
Las Vegas 2
Lexington 2
Luxembourg 2
Macerata 2
Madrid 2
Totale 8.112
Nome #
Designing novel immunocombinations in metastatic renal cell carcinoma 152
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 128
Immunotherapy in genitourinary cancers: Where are we going? 120
Are liver nested stromal epithelial tumors always low aggressive? 116
Microbiome and cancers, with focus on genitourinary tumors 105
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 103
Molecular diagnostics in uro-oncology 96
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 96
From undergraduate medical school student to visible pathologist 93
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 92
Is There a Role for Immunotherapy in Prostate Cancer? 89
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 86
Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? 85
Clinicopathologic analysis of upper urinary tract carcinoma with variant histology 84
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 84
Pd-l1 inhibitors for the treatment of prostate cancer 84
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 82
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 82
Predicting future cancer burden in the United States by artificial neural networks 82
Emerging prognostic biomarkers in testicular germ cell tumors: Looking beyond established practice 82
The 1996 European Urology Focus on Preneoplastic Lesions of the Prostate 82
The human microbiota and prostate cancer: Friend or foe? 80
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer 80
Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians 79
Epigenetic modifications and modulators in prostate cancer 79
Exploring the Spectrum of Kidney Ciliopathies 79
Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion 79
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 78
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 77
Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View 77
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 77
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 77
Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy? 76
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 76
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 76
Biomarkers of angiogenesis and clinical outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Randomized Phase III METEOR Trial 76
Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer 75
Pathology and molecular updates in tumors of the prostate: towards a personalized approach. 74
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution 74
Molecular characterization of testicular germ cell tumors using tissue microdissection 73
Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019;76:871 73
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 72
Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View 72
Digital frozen section of the prostate surface during radical prostatectomy: a novel approach to evaluate surgical margins 71
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 70
p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading 70
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 70
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 69
Quick steps toward precision medicine in renal cell carcinoma 69
Uropathologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance 69
Pathology without microscope: From a projection screen to a virtual slide 69
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 69
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 69
Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology 69
Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma 69
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 68
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 68
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 68
Variants of Bladder Cancer: The Pathologist's Point of View 68
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 68
Syndrome of inappropriate antidiuresis in prostate adenocarcinoma with neuroendocrine differentiation: a case report and literature review 67
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 67
Immunotherapy for urothelial cancer: from the diagnostic pathologist’s point of view 67
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay 67
Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives 67
Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice 66
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 66
Considerations on current and future issues related to reproducibility and accuracy in prostate cancer grading 66
Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule 66
Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples 66
Emerging molecular technologies in genitourinary tumors 65
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype 65
Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer 64
Immunotherapy and radiation therapy in renal cell carcinoma 64
Digital diagnostics and artificial intelligence in prostate cancer treatment in 5 years from now 64
Editorial: Emerging biomarkers in genitourinary tumors 63
The identification of immunological biomarkers in kidney cancers 63
Epigenetic modulations and lineage plasticity in advanced prostate cancer 63
Treating prostate cancer by antibody-drug conjugates 63
Current and future perspectives of digital microscopy with fluorescence confocal microscope for prostate tissue interpretation: A narrative review 63
pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging 62
Prostate cancer grading in 2018: Limitations, implementations, cribriform morphology, and biological markers 62
Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC 62
Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy 62
The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors 62
null 62
Immune checkpoint inhibitors for the treatment of bladder cancer 62
Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vasc Interv Radiol 2018;29:589–97. Eur Urol 2018;74:525–6: Could Morphologic Changes in Periprostatic Arteries Have an Influence on Prostatic Artery Embolization? 61
PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness 61
Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2? 61
Variants and new entities of bladder cancer 61
Renal Cell Carcinoma: genomic landscape and clinical implications 61
Bone targeting agents in patients with metastatic prostate cancer: State of the art 61
Emerging molecular technologies in renal cell carcinoma: Liquid biopsy 60
Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies 60
Biphasic Tumors of the Urogenital Tract: Selected Topics 60
Re: Multi-institutional Re-evaluation of Prognostic Factors in Chromophobe Renal Cell Carcinoma: Proposal of a Novel Two-tiered Grading Scheme 59
Pd-l1 testing for urothelial carcinoma: Interchangeability, reliability and future perspectives 59
Liquid biopsy in the clinical management of bladder cancer: current status and future developments 58
Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: Where we stand and where we go 58
Totale 7.391
Categoria #
all - tutte 68.234
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.234


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020142 0 0 0 0 16 4 15 2 21 11 31 42
2020/20212.174 38 40 68 63 224 762 182 186 138 200 230 43
2021/20221.512 267 171 79 23 50 179 28 90 128 116 87 294
2022/20234.130 266 288 156 313 218 1.705 3 234 680 16 178 73
2023/20241.611 282 45 138 162 248 358 22 49 5 57 24 221
2024/2025736 380 230 35 52 39 0 0 0 0 0 0 0
Totale 10.369